• Vaccine Name: Cancer Vaccine using E7 protein of human papillomavirus 16 and Quil-A
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004228
• Type: Subunit vaccine
• Status: Licensed
• Antigen: Peptide GF001, comprising the H-2Db-restricted minimal CTL epitope of HPV16 E7 protein (Fernando et al., 1998).
• E7 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001263
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6J
• Vaccination Protocol: Mice (8 to 10 per group) were immunized s.c. at the base of the tail with 50 µg of E7GST protein, or 50 µg OVA as control, and 10 µg of Quil-A or 50 µg of Algammulin as adjuvant (Fernando et al., 1998).
• Challenge Protocol: Mice were challenged with 3 x 10^6 cells of EL4.E7 tumor or 2 x 10^6 cells of C3 cells 14 days after the last immunization (Fernando et al., 1998).
• Efficacy: Growth of EL4.E7 was reduced following immunization with E7 and Quil-A (an adjuvant that induced a Th1-type response to E7) or with GF001 and Quil-A (Fernando et al., 1998).